Vanda Pharmaceuticals Inc.
A Washington, D.C.-based biopharmaceutical company that develops medicines for brain and nervous-system conditions. Its products include Hetlioz, a treatment for a rare sleep disorder in which totally blind people's internal body clocks drift because they cannot perceive light, and Fanapt, an antipsychotic for schizophrenia. Founded in 2003 by a Greek-American scientist who worked on the Human Genome Project, the company takes its name from the Vanda, a genus of orchids.
Sold 156.2K
Sold 42.4K
Sold 42.4K
Sold 42.4K
Sold 30.8K
Granted 41.6K
Granted 41.6K
Granted 41.6K
Granted 41.6K
Granted 41.6K
Granted 98.7K
Granted 80.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Polymeropoulos Mihael HristosPresident and CEO, Director, Chairman of the Board · 1 transaction | -5.5% | 2.70M | — | — | 156.2K |
| Birznieks GuntherSVP, Business Development · 1 transaction | -7.9% | 494.2K | — | — | 42.4K |
| Moran Kevin PatrickSVP, CFO & Treasurer · 1 transaction | -9.3% | 412.6K | — | — | 42.4K |
| Williams TimothySVP & General Counsel · 1 transaction | -10.1% | 377.4K | — | — | 42.4K |
| Wijkstrom JoakimSVP, Chief Marketing Officer · 1 transaction | -8.5% | 333.5K | — | — | 30.8K |
| Dugan Richard WDirector · 1 transaction | +23.4% | 219.1K | 41.6K | — | — |
| Chrousos PhaedraDirector · 1 transaction | +33.7% | 164.9K | 41.6K | — | — |
| Ward Anne SempowskiDirector · 1 transaction | +34.9% | 160.7K | 41.6K | — | — |
| Honore TageDirector · 1 transaction | +44.5% | 135.1K | 41.6K | — | — |
| Mitchell Stephen RayDirector · 2 transactions | +16.2% | 112.8K | 41.6K | — | — |
| Duncan Charles CliffDirector · 2 transactions | — | 98.7K | 98.7K | — | — |
| McGuire Daniel PatrickSVP, GC and Secretary · 1 transaction | — | 6.0K | 80.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -314.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.